Self-assembling peptide IEIK13 for intraoperative hemostasis in cranial neurosurgery: clinical trial on efficacy and safety
Verbraeken, Barbara Plazier, Mark Put, Eric Meeuws, Sacha Roosen, Gert Ughratdar, Ismail Zisakis, Athanasios Vergani, Francesco Ganau, Mario Plaha, Puneet
Verbraeken, Barbara
Plazier, Mark
Put, Eric
Meeuws, Sacha
Roosen, Gert
Ughratdar, Ismail
Zisakis, Athanasios
Vergani, Francesco
Ganau, Mario
Plaha, Puneet
Affiliation
Antwerp University Hospital; University of Antwerp; Jessa Hospital; University Hospitals Birmingham NHS Foundation Trust; King's College Hospital NHS Foundation Trust; Oxford University; Lille University Hospital
Other Contributors
Publication date
2025-03-05
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Objective: This article describes the results of the first-in-human prospective clinical trial of a hemostatic hydrogel of the self-assembling peptide IEIK13 for hemostasis in intracranial surgery. Both safety and efficacy of IEIK13 for intraoperative hemostasis of oozing bleeding were evaluated in this multicenter trial.
Methods: A total of 80 participants underwent a surgical intervention, during which 203 intradural bleeding sites were treated with IEIK13. Hemostasis was evaluated at 30 seconds and again at 1, 2, 3, and 6 minutes after application. A performance goal of >70% of bleeding sites reaching hemostasis within 3 minutes after application of IEIK13 was used to demonstrate noninferiority in statistical analysis. Clinical safety evaluation was performed postoperatively, at hospital discharge, and at 1 and 3 months after surgery. This included follow-up radiological imaging within the first 72 hours postoperatively and at 3 months.
Results: Hemostasis was achieved within 3 minutes in 94.1% of bleeding sites, and within 6 minutes in 95.6% of bleeding sites. Subanalysis revealed that hemostasis occurred within the first minute in 89.2% of cases. There were no intraoperative device deficiencies. Results of the safety assessment did not raise any specific concerns. The nature and rate of adverse events did not significantly differ from what is typically expected in neurosurgical practice.
Conclusions: IEIK13 is effective and safe for hemostasis of oozing bleeding during intracranial neurosurgery. Based on this trial, the transparent IEIK13 hydrogel is a useful addition to the neurosurgical hemostasis toolbox.
Citation
Verbraeken B, Plazier M, Put E, Meeuws S, Roosen G, Ughratdar I, Zisakis A, Vergani F, Ganau M, Plaha P, Apostolopoulos V, Feyen B, Raymaekers V, Aboukais R, Menovsky T. Self-Assembling Peptide IEIK13 for Intraoperative Hemostasis in Cranial Neurosurgery: Clinical Trial on Efficacy and Safety. World Neurosurg. 2025 May;197:123856. doi: 10.1016/j.wneu.2025.123856. Epub 2025 Mar 5.
Type
Article